Artem

About Artem Andrianov, Ph.D., MBA

Professional in the integration of data-driven Risk-based Quality Management (RBQM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, Health 2.0, DGGF, etc. 18+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RBQM research to new frontiers for CROs, pharma and biotech companies.

Dec 2013

2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development
Gallery
2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

News

2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

By Artem Andrianov, Ph.D., MBA|2016-11-16T18:35:48+02:00December 23, 2013|News|Comments Off on 2013 Year in review: Clinical Development[:de]2013 Year in review: Clinical Development

Average clinical trials Submissions in 2013: Phase I - 314 studies per Quartile, phase II - 233 studies per Quartile, Phase III - 237 studies per Quartile; R&D Spending in Pharma goes down by 5% in 2013 and in Generics jumps by 18%: Major partnership: [...]